Filtricine, Inc. is pioneering a novel approach to cancer care through its proprietary nutritional regimen known as Tality, which is currently under clinical investigation. The foundation of this innovative product is based on the concept of Targeted Nutrients Deprivation (TND), discovered by the company's founders during their research at Stanford University. TND focuses on depriving cancer cells of non-essential amino acids (NEAAs), which are crucial for their survival and proliferation. By formulating foods that eliminate these NEAAs while maintaining essential nutrients, Tality aims to provide cancer patients with a means to manage their condition effectively. Early clinical studies have shown that Tality is nutritionally complete, safe, and may lead to reductions in prostate-specific antigen (PSA) levels in prostate cancer patients.

In addition to the Tality meal plan, Filtricine is also developing a modified dialysis technology designed to selectively remove nutrients that cancer cells require. This innovative approach aims to enhance the effectiveness of the TND diet by accelerating the depletion of NEAAs from the bloodstream. The combination of the Tality diet and modified dialysis could potentially offer a powerful strategy for cancer treatment, allowing for a more efficient means of starving cancer cells while supporting the health of normal cells. Filtricine's ongoing clinical trials at Stanford University are crucial for validating the safety and efficacy of these groundbreaking technologies in cancer care.

United States

Filtricine develops and commercializes food products that can treat cancer and metabolic diseases. The company is a spinout from Prof. Michael Snyder's lab at Stanford University School of Medicine. A small-scale clinical trial in prostate cancer patients has been conducted at Stanford University showing promising results. Visit our website at www.filtricine.com to learn more, or contact us at gracexlyang at filtricine dot com

Filtricine

Company Details